PDCD1 and rectal cancer: Additionally, in our institutional cohort, we found that in advanced rectal cancer patients treated with anti-PD-1 therapy, responders exhibited a higher density of TLS infiltration compared to non-responders, with a trend toward a greater proportion of mature TLS (Fig. 5J, Table S3).